Molecular Diagnostics for Lung Cancer

2019 ◽  
pp. 27-41
Author(s):  
Ashok Kumar ◽  
Ashwani Tandon
Keyword(s):  
Lung Cancer ◽  
Molecular Diagnostics

scholarly journals EP1.09-14 Best Practice Session on Lung Cancer Molecular Diagnostics in the Netherlands to Enhance Testing Proportions Nationwide

2019 ◽  
Vol 14 (10) ◽  
pp. S1003
Author(s):  
C. Kuijpers ◽  
M. Van Den Heuvel ◽  
A. Van Lindert ◽  
R. Damhuis ◽  
S. Willems
Keyword(s):  
Lung Cancer ◽  
The Netherlands ◽  
Molecular Diagnostics ◽  
Best Practice ◽  
Practice Session

Expanded molecular routine testing for targetable mutations in non-small cell lung cancer to reveal frequent co-occuring mutations.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e20596-e20596
Author(s):  
Anna Kostenko ◽  
Jana Fassunke ◽  
Susanne Steinhauser ◽  
Matthias Scheffler ◽  
Sabine Merkelbach-Bruse ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Molecular Diagnostics ◽  
Clinical Data ◽  
Single Gene ◽  
Genomic Medicine ◽  
Genetic Alterations ◽  
Clinical Diagnostics ◽  
Central Platform ◽  
The Impact

e20596 Background: Using next-gen sequencing of predefined gene panels in routine clinical diagnostics of lung cancer allows, in contrast to single-gene assays, assessment of co-occuring mutations, which might underly heterogeneity of response to targeted drugs and survival. The Network Genomic Medicine (NGM) performs high sensitive next generation sequencing (NGS) based routine molecular diagnostics on a central platform for about 5000 inoperable lung cancer patients (pts) annually in Germany. Methods: NGS panel used in NGM consists of 17 genes to cover potentially targetable aberrations. Mutation analyses were run on an Illumina (MySeq) platform, while FISH analyses were performed separately. In 2016, we have started the evaluation of all NGM pts with available clinical data who had received NGS-based molecular diagnostics. In particular, we have focused on non-squamous (non-sq) and squamous (sq) NSCLC pts with co-occurring mutations: their frequency, significance and impact on overall survival. Results: From 2014 molecular genotyping was performed for 7,893 NGM pts (n = 7,246 NSCLC (5,667 non-sq and 1,487 sq pts) and n = 489 SCLC) with eligible clinical data. Genetic alterations in transformation-associated pathways were found in 79 % of all NSCLC pts. Furthermore, co-occurring mutations were detected in 39 % of these pts: 40 % in non-sq and 37 % in sq NSCLC. 11 % of pts had more than 2 co-occurring mutations. 1 % of all pts had 5 co-occurring mutations. The most frequent paired mutations were KRAS, EGFR and MET each with TP53 in non-sq and FRGF1 and TP53 in sq NSCLC. The incidences and significance of 3, 4 and 5 co-mutations as well as the impact of these co-occurring mutations on overall survival will be presented. Conclusions: Frequent occurrence of co-occuring mutations in transformation – associated pathways underlines the genetic heterogeneity also of lung cancer with classical driver mutation and the impact of co-occurring mutations on survival. This work confirms the use of molecular multiplex testing in routine molecular diagnostics of NSCLC. Assessment of co-occuring mutations will help to further specify genetically defined subgroups of lung cancer with therapeutic relevance.

Molecular Biomarkers Workshop: a European Strategy for Developing Lung Cancer Molecular Diagnostics in High Risk Populations

Lung Cancer ◽  
2001 ◽  
Vol 31 (2-3) ◽  
pp. 339-345 ◽  
Author(s):  
J.K. Field ◽  
C. Brambilla ◽  
F.R. Hirsch ◽  
W. Hittelman ◽  
M. Hogan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Molecular Diagnostics ◽  
Molecular Biomarkers ◽  
High Risk Populations

Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging

2015 ◽  
Vol 15 (6) ◽  
pp. 801-813 ◽  
Author(s):  
Mattia Boeri ◽  
Stefano Sestini ◽  
Orazio Fortunato ◽  
Carla Verri ◽  
Paola Suatoni ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Molecular Diagnostics ◽  
False Positive ◽  
Cancer Imaging ◽  
Recent Advances

Molecular diagnostics of a single multifocal non-small cell lung cancer case using targeted next generation sequencing

2012 ◽  
Vol 462 (2) ◽  
pp. 249-254 ◽  
Author(s):  
Willemina R. R. Geurts-Giele ◽  
Albertina W. Dirkx-van der Velden ◽  
Natascha M. M. T. Bartalits ◽  
Leon C. Verhoog ◽  
Wessel E. J. J. Hanselaar ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Small Cell Lung Cancer ◽  
Molecular Diagnostics ◽  
Small Cell ◽  
Cancer Case ◽  
Lung Cancer Case ◽  
Small Cell Lung ◽  
Targeted Next Generation Sequencing ◽  
Generation Sequencing

scholarly journals Ancillary Testing in Lung Cancer Diagnosis

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
William Dubinski ◽  
Natasha B. Leighl ◽  
Ming-Sound Tsao ◽  
David M. Hwang
Keyword(s):  
Lung Cancer ◽  
Molecular Diagnostics ◽  
Cancer Diagnosis ◽  
Targeted Therapies ◽  
Patient Management ◽  
Predictive Information ◽  
Lung Cancers ◽  
Pathologic Diagnosis ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer

The pathologic diagnosis of lung cancer historically has relied primarily on morphologic features of tumors in histologic sections. With the emergence of new targeted therapies, the pathologist is called upon increasingly to provide not only accurate typing of lung cancers, but also to provide prognostic and predictive information, based on a growing number of ancillary tests, that may have significant impact on patient management. This review provides an overview of ancillary tests currently used in the pathologic diagnosis of lung cancer, with a focus on immunohistochemistry and molecular diagnostics.

scholarly journals Molecular diagnostics of lung cancer in the clinic

2017 ◽  
Vol 6 (5) ◽  
pp. 560-569 ◽  
Author(s):  
Lynette Sholl
Keyword(s):  
Lung Cancer ◽  
Molecular Diagnostics
Sign in / Sign up

Export Citation Format

Share Document